{"url_path":"/sec/lipo/8-k/2026-07-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1347242/0001753926-26-001173-index.html","accession_number":"0001753926-26-001173","cik":"0001347242","ticker":"LIPO","issuer_name":"LIPELLA PHARMACEUTICALS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1347242/0001753926-26-001173-index.html","primary_entity_key":"0001347242","primary_entity_name":"LIPELLA PHARMACEUTICALS INC."},"word_count":138,"has_tables":true,"body_markdown":"**Item\n9.01    Financial Statements and Exhibits.**\n\n \n\n**(d)\nExhibits**\n\n \n\n**Exhibit**\n\n**Number** \n\n**Description**\n\n[2.1](g085807_ex2-1.htm)\n[Order (I) Approving the Sales or other Acquisition Transaction for the Assets, (II) Authorizing the Sales Free and Clear of all Encumbrances, (III) Authorizing the Assumption and Assignment of Certain Executory Contracts and Unexpired Leases, and (IV) Granting Related Relief [Doc. No. 115]](g085807_ex2-1.htm)\n\n[2.2](g085807_ex2-2.htm)\n[Asset Purchase Agreement among Lipella Pharmaceuticals Inc. and XRAIY LLC, or its designee(s), dated as of May 14, 2026](g085807_ex2-2.htm)\n\n104\nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n 2 \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf\nby the undersigned hereunto duly authorized.\n\n \n\nDate: July 15, 2026\nLipella Pharmaceuticals,\nInc.\n\n \n \n \n\n \nBy:\n   /s/ Jonathan Kaufman\n\n \n \nName:  Jonathan Kaufman\n\n \n \nTitle:  Chief Executive\nOfficer\n\n \n\n \n\n \n\n 3"}